HRMY vs NBIX
HRMY: Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor antagonist for narcolepsy, with an expanding pipeline in rare epilepsy and sleep disorders. NBIX: Neurocrine is a profitably growing, neuroscience-focused biotech commercializing novel treatments for movement disorders, endocrine diseases, and psychiatric conditions with expanding late-stage pipeline and recent M&A.
Side-by-side fundamentals
| Metric | HRMY | NBIX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.86 | $172.69 | |
| Market cap as of 2026-07-23 | $2.0B | $17.8B | |
| P/E as of 2026-07-23 | 13.86 | 26.70 | HRMY lower |
| PEG as of 2026-07-23 | 0.20 | 0.23 | HRMY lower |
| Net margin as of 2026-07-23 | +16.2% | +21.6% | NBIX higher |
| Gross margin as of 2026-07-23 | +76.5% | +98.2% | NBIX higher |
| Operating margin as of 2026-07-23 | +21.1% | +25.4% | NBIX higher |
| ROE as of 2026-07-23 | +17.2% | +21.6% | NBIX higher |
| ROA as of 2026-07-23 | +12.0% | +15.1% | NBIX higher |
| Debt / equity as of 2026-07-23 | 0.17 | 0.00 | NBIX lower |
| Revenue growth (YoY) as of 2026-07-23 | +20.7% | +28.6% | NBIX higher |
| Revenue CAGR (3y) SEC XBRL | +25.6% | +24.3% | HRMY higher |
| Beta as of 2026-07-23 | 0.91 | 0.39 | |
| 1-year return as of 2026-07-22 close | +4.5% | +30.1% | NBIX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.